NCT02656706View on ClinicalTrials.gov

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

March 31, 2019

Study Completion Date

July 31, 2025

Conditions

Melanoma

Interventions

DRUG

Ipilumumab

DRUG

Nivolumab

Trial Locations (1)

02903/02906

Rhode Island Hospital and The Miriam Hospital, Providence

Sponsors

Lead Sponsor

Brown University

All Listed Sponsors

collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

lead

Brown University

OTHER